Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab

Ann Hematol. 2021 Aug;100(8):2117-2119. doi: 10.1007/s00277-020-04236-7. Epub 2020 Aug 27.

Affiliations

¹ Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
² Clinical and Molecular Department, Oncologia B Policlinico Umberto I, Sapienza University, Rome, Italy.
³ Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto 1, Sapienza University, Via Benevento 6, 00161, Rome, Italy. [email protected].

PMID: 32856142
DOI: 10.1007/s00277-020-04236-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Squamous Cell / complications
Carcinoma, Squamous Cell / drug therapy*
Humans
Male
Nitriles / therapeutic use*
Primary Myelofibrosis / complications
Primary Myelofibrosis / drug therapy*
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Skin Neoplasms / complications
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Agents, Immunological
Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
cemiplimab
ruxolitinib